Cite
Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase α (DGKα)/NOX4 axis.
MLA
Chen, Jie, et al. “Tumor-Associated Macrophage (TAM)-Secreted CCL22 Confers Cisplatin Resistance of Esophageal Squamous Cell Carcinoma (ESCC) Cells via Regulating the Activity of Diacylglycerol Kinase α (DGKα)/NOX4 Axis.” Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, vol. 73, Mar. 2024, p. 101055. EBSCOhost, https://doi.org/10.1016/j.drup.2024.101055.
APA
Chen, J., Zhao, D., Zhang, L., Zhang, J., Xiao, Y., Wu, Q., Wang, Y., & Zhan, Q. (2024). Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase α (DGKα)/NOX4 axis. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 73, 101055. https://doi.org/10.1016/j.drup.2024.101055
Chicago
Chen, Jie, Di Zhao, Lingyuan Zhang, Jing Zhang, Yuanfan Xiao, Qingnan Wu, Yan Wang, and Qimin Zhan. 2024. “Tumor-Associated Macrophage (TAM)-Secreted CCL22 Confers Cisplatin Resistance of Esophageal Squamous Cell Carcinoma (ESCC) Cells via Regulating the Activity of Diacylglycerol Kinase α (DGKα)/NOX4 Axis.” Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 73 (March): 101055. doi:10.1016/j.drup.2024.101055.